Cardiovascular disease and kidney failure continue to place enormous pressure on healthcare systems worldwide, creating demand for medical technologies that deliver longer lasting treatment outcomes while reducing the need for repeat surgical procedures. Conventional vascular grafts and replacement implants can deteriorate over time, often requiring additional interventions that increase healthcare costs and affect patients’ quality of life. Dutch MedTech company Xeltis is developing a new generation of restorative implants that encourage the body to rebuild its own living tissue, offering a fundamentally different approach to vascular repair. The company has now secured fresh investment to expand commercial adoption in Europe and accelerate clinical development in the United States.
Xeltis has raised an additional €20.5 million from new and existing investors in a funding round led by Horizon 3 Healthcare, with participation from the European Innovation Council, Invest NL, VI Partners, EQT Life Sciences, DaVita, and other current shareholders.
The investment strengthens the company’s financial position as it advances commercial expansion, clinical programmes, manufacturing growth, and regulatory milestones across international markets.
Developing Living Blood Vessels
Founded in 2006, Xeltis develops restorative cardiovascular implants designed to become part of the patient’s own body.
Its proprietary Restorex platform uses advanced polymer implants that gradually stimulate the body’s natural healing process.
Over time, the implant is replaced by newly formed living tissue while the original polymer safely disappears, leaving behind a natural blood vessel created by the patient.
The company believes this restorative approach offers significant advantages over conventional synthetic implants by supporting longer lasting clinical outcomes while reducing the likelihood of repeat interventions.
Commercial Expansion of aXess
Xeltis’ most advanced product, aXess, has been developed for patients requiring vascular access for haemodialysis treatment.
The implant recently received CE Mark approval and is now being introduced commercially across Europe.
Unlike conventional vascular access options, aXess is designed to regenerate into living vascular tissue capable of supporting long term dialysis treatment.
The company recently announced the successful treatment of its first commercial patient in Germany, marking an important milestone in its European commercial rollout.
Alongside commercial expansion, enrolment continues in the United States pivotal clinical trial, which has already progressed beyond the halfway point.
Advancing a Broader Clinical Pipeline
Beyond haemodialysis vascular access, Xeltis is applying its restorative technology across additional cardiovascular applications.
Its development pipeline includes programmes focused on coronary artery bypass grafting and peripheral arterial disease, both of which represent significant unmet clinical needs worldwide.
The company believes the same regenerative technology can be adapted for multiple vascular and cardiovascular conditions where durable biological repair offers important advantages over existing treatment approaches.
Continued clinical development remains a central priority as the company expands the potential use of its platform.
Preparing for Global Growth
The newly secured funding will support completion of the ongoing United States pivotal trial for aXess while preparing regulatory submissions and commercial launch activities in the American market.
Additional investment will accelerate the European rollout of aXess while supporting manufacturing expansion to meet growing demand.
The company also plans to continue advancing its broader research and clinical programmes as it strengthens its international presence.
This latest financing builds upon earlier investment secured to support long term product development, commercialisation, and clinical execution.
Transforming Vascular Medicine
As healthcare increasingly shifts towards regenerative therapies that restore natural biological function, technologies capable of helping the body repair itself are attracting growing interest from clinicians and investors alike.
Xeltis is positioning itself at the forefront of this transition by developing implants that work with the body’s own regenerative capabilities rather than acting as permanent synthetic replacements.
With fresh funding, expanding commercial adoption, and continued progress across multiple clinical programmes, the company is accelerating its mission to bring restorative cardiovascular therapies to patients worldwide. By enabling the creation of living blood vessels that grow naturally within the body, Xeltis aims to improve long term patient outcomes while reshaping the future of vascular and cardiovascular treatment.
